About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Eurasian Hematology-Oncology Group
http://www.ehog.net/
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
8th Eurasian Hematology Oncology Summit
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Palliative & Supportive Care
COVID-19
Basic Science
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
7th Eurasian Hematology Oncology Summit
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Xth Eurasian Hematology-Oncology Congress
Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
E
Debates in MPNs: Hydroxyurea is the Optimal 1L Treatment for Young PV Patients
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Emre Eşkazan
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Emre Eşkazan
0 views
February 21, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
MDS and MPN
12:28
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Next Questions in MDS
Feat.
G. Garcia-Manero
10:11
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Case Presentation: A Patient With Polycythemia, Thrombocytopenia, &a…
Feat.
M. Mittelman
20:35
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Treatment Options for MDS With Ring Sideroblasts: A Case-Based Discu…
Feat.
M. Çetiner
14:36
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Optimizing the Management of Low-Risk MDS
Feat.
U. Platzbecker
19:32
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current State-of-the-Art in MDS
Feat.
M. Mittelman
10:08
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Advances and Unmet Needs in MPN Treatment
Feat.
D. Cilloni
06:58
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in MPNs: IFN-α is the Optimal 1L Treatment for Young PV Pati…
Feat.
R. Kusec
08:47
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in MPNs: Hydroxyurea is the Optimal 1L Treatment for Young P…
Feat.
E. Eşkazan
07:58
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Updates in the Prognosis and Treatment of Myelofibrosis
Feat.
S. Koçak Toprak
10:50
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
CBL Mutated MPNs: Overview and Case Discussion
Feat.
A. Lucchesi
19:05
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Key Biological and Clinical Developments in MPNs
Feat.
T. Mughal
